Non-invasive Biomarkers for Allograft Rejection

Wednesday, October 2, 2019 - 14:00 to 15:00

View Archive

Q&A Handout: Covering speaker responses to questions not addressed during the live session.

Speakers:
Barbara Murphy, MD, MB, BAO, BCh, FRCPI • Murray M. Rosenberg Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY
Peter Nickerson, BSc (Med), MD, FRCPC, FCAHS • Distinguished Professor of Internal Medicine and Immunology, University of Manitoba Max Rady College of Medicine, Winnipeg, MB

Moderator:
Peter Heeger, MD • Professor of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY

Objectives for the "Non-invasive Biomarkers for Allograft Rejection" webinar include:

  1. Discussing the role of Pre-Transplant HLA Molecular Mismatch as a Prognostic Biomarker of Primary Alloimmunity.
  2. Discussing the role of Pre-Transplant HLA Molecular Mismatch as a Predictive Biomarker of CNI-based therapy requirements to control Primary Alloimmunity.
  3. Discussing the impact of subclinical rejection on longterm survival and the need for non-invasive markers of allograft rejection.
  4. Discussing the role of peripheral gene expression for the detection of subclinical rejection.
- - - - -

AST would like to thank the Community of Transplant Scientists (COTS) and the Transplant Diagnostics Community of Practice (TxDx COP) for recommending biomarkers for allograft rejection as a topic for the 2019-2020 T3 series. Learn more about AST's COPs at www.myast.org/cops.

Education Category: 
Series category: 
T3: Timely Topics in Transplantion